logo
搜索
菜单

Clearance的搜索结果

当前1/4页
排序: 最近更新
15.5: Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration 01:23 min
15.5: Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
13.22: Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant 01:25 min
13.22: Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
13.20: Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance 01:25 min
13.20: Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance
13.19: Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate 01:25 min
13.19: Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
13.16: Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug 01:14 min
13.16: Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
13.15: Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow 01:26 min
13.15: Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
13.14: Pharmacokinetics in Pediatric Patients: Drug Excretion 01:26 min
13.14: Pharmacokinetics in Pediatric Patients: Drug Excretion
13.7: Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion 01:18 min
13.7: Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
13.6: Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism 01:18 min
13.6: Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
12.3: Dosage Regimen: Multiple Oral Dosage 01:25 min
12.3: Dosage Regimen: Multiple Oral Dosage
Determining the Phagocytic Activity of Clinical Antibody Samples 10.3791/3588-v
Determining the Phagocytic Activity of Clinical Antibody Samples
8.10: Chronopharmacokinetics: Time-Dependent Pharmacokinetics 01:20 min
8.10: Chronopharmacokinetics: Time-Dependent Pharmacokinetics
8.8: Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance 01:23 min
8.8: Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
8.2: Nonlinear Pharmacokinetics: Causes of Nonlinearity 01:22 min
8.2: Nonlinear Pharmacokinetics: Causes of Nonlinearity
7.29: Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters 00:54 min
7.29: Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
7.25: Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis 00:59 min
7.25: Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
7.23: Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance 01:07 min
7.23: Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
7.21: Physiological Pharmacokinetic Models: Assumption with Protein Binding 01:13 min
7.21: Physiological Pharmacokinetic Models: Assumption with Protein Binding
7.13: Two-Compartment Open Model: IV Bolus Administration 01:18 min
7.13: Two-Compartment Open Model: IV Bolus Administration
7.11: Multicompartment Models: Overview 01:14 min
7.11: Multicompartment Models: Overview
返回顶部